

Eisai, Merck, Pfizer join Accenture to build R&D cloud platform

10 October 2014 | News | By BioSpectrum Bureau

Eisai, Merck, Pfizer join Accenture to build R&D cloud platform



Eisai, Merck, and Pfizer have joined forces to build a standards-driven platform powered by Oracle hardware and software to help pharmaceutical companies simplify and speed drug development.

Accenture Life Sciences cloud for R&D solution is a new IT platform offering a transformation of the R&D technology landscape.

"We have helped these companies successfully improve trial efficiencies, cut trial costs and enhance the productivity of trial participants," said Accenture in a note.

This cloud platform offers a forward-looking, transformation of the R&D technology landscape providing new ways to use data across the development lifecycle to bring life-enhancing products to patients faster.

The cloud brings together multiple internal and external data sources across clinical, safety, regulatory and operational functions into a single analytics platform, creating actionable insights to accelerate drug development and improve patient outcomes.